Cardiol Therapeutics Inc. (CRDL)
1.12
0.00 (0.00%)
At close: Mar 24, 2025, 3:59 PM
1.14
1.44%
After-hours: Mar 24, 2025, 07:55 PM EDT
0.00% (1D)
| Bid | 1.09 |
| Market Cap | 91.4M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -42.22M |
| EPS (ttm) | -0.38 |
| PE Ratio (ttm) | -2.95 |
| Forward PE | -3.45 |
| Analyst | Buy |
| Ask | 1.18 |
| Volume | 195,862 |
| Avg. Volume (20D) | 258,391 |
| Open | 1.13 |
| Previous Close | 1.12 |
| Day's Range | 1.09 - 1.18 |
| 52-Week Range | 1.02 - 3.12 |
| Beta | 0.57 |
About CRDL
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respirat...
Sector Healthcare
IPO Date Jan 15, 2019
Employees 22
Stock Exchange NASDAQ
Ticker Symbol CRDL
Website https://www.cardiolrx.com
Analyst Forecast
According to 3 analyst ratings, the average rating for CRDL stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 703.57% from the latest price.
Stock Forecasts5 months ago
-6.63%
Cardiol Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
5 months ago
+3.7%
Cardiol Therapeutics shares are trading lower after the company announced a preliminary prospectus for a proposed public offering of common stock, size or amount not disclosed.
